Download
1 / 4
40 likes | 60 Views
Adcetris contains Brentuximab Vedotin, which is an ADC. This antibody is a chimeric IgG1 directed against CD30, and the small molecule (MMAE) is a microtubule disrupting agent. MMAE, the small molecule, is covalently attached to the antibody via a linker. The data suggest that the anticancer activity of this medicine is due to the binding of the ADC to CD30-expressing cells, internalization of the ADC-CD30 complex, and the release of MMAE via proteolytic cleavage. The binding of MMAE (the small molecule) to tubulin disturbs the cell's microtubule network, giving rise to cell cycle arrest and a
E N D
Information for the Patient About Brentuximab Vedotin What Adcetris is? Adcetris specifically contains the active substance named brentuximab vedotin. It is an anti-cancer agent, made up of a monoclonal antibody associated with a substance intended to destroy cancerous cells. This substance is delivered to cancerous cells by the monoclonal antibody. A monoclonal antibody is mainly a protein which identifies certain cancerous cells. What ADCETRIS is used for? ADCETRIS is used for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). ADCETRIS is used to treat adult patients with CD30+ HL at increased risk of relapse/progression following autologous stem cell transplant (ASCT). ADCETRIS is used to treat adult patients with relapsed/refractory CD30+ Hodgkin lymphoma (HL) after ASCT, or after minimum two prior therapies when ASCT or multi-agent chemo is not an option. ADCETRIS along with the cyclophosphamide, doxorubicin and prednisone (CHP) is used to treat adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). It is also used to treat adult patients with relapsed/refractory sALCL. ADCETRIS is used to treat adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least one earlier systemic therapy. Dosage: The dosage of Adcetris depends on the patient's body weight. The standard dose administered along with doxorubicin, vinblastine and dacarbazine is 1.2 mg/kg given every two weeks for six months. The standard dose of Adcetris administered along with the drugs cyclophosphamide, doxorubicin and prednisone is 1.8 mg/kg administered every three weeks for approximately 4 to 6 months. Following the first Adcetris dose together with chemotherapy, a healthcare professional may also give a medication that will help prevent the formation or decrease the severity of reduced white blood cell count which could increase the probability of infection. Patients should report to their healthcare team in case they have kidney/liver problems as their healthcare professional may lower their starting dose or may not prescribe Adcetris. The standard dose of Adcetris administered alone is 1.8 mg/kg, administered once every 3 weeks for no more than a year. A doctor may lower the starting dose to 1.2 mg per kg in case patients have kidney/liver problems. This medication is to be administered to adults only. Use of Adcetris is not suitable for children. How Adcetris is given? This medication is given to patients into a vein (intravenously) as an infusion. It is given by a healthcare practitioner over 30 minutes. Respective patients will also be monitored during as well as following the infusion. Possible side effects: Like all other medicines, Adcetris may also cause side effects, although not every individual gets them. The following very common side effects have been reported with Adcetris alone: •Decrease in weight •Infection
•Nausea •Abdominal pain •Itching •Muscle pain •Joint pain or painful •Swollen joints •Decreased level of white blood cells •Upper respiratory tract infection Warnings and Precautions: •Avoid using Adcetris in case patients are allergic to brentuximab or any of the other existing ingredients of this medication. •Do not use Adcetris in case patients are currently using a drug named bleomycin, an anti- cancer agent. •Patients will be monitored for regular blood tests in order to make sure that it is safe for them to receive this drug. •Patients should inform their doctor if they are taking any other drugs, if they have administered any recently, or if they start taking new ones. This includes herbal and other medications patients can get without a prescription. •Patients and their partner must use two methods of apt contraception while on treatment with this medicine. Women are advised to continue using contraception for six months after the last dose. •Patients should avoid using this drug if they are pregnant unless they and their doctor determine that the benefit to them outweighs the potential risk to the unborn baby. •Patients must tell their doctor prior to and while on treatment if they are pregnant, think they may be pregnant, or are planning to get pregnant. •If patients are breast-feeding, they must discuss with their healthcare professional whether they should take this medication. •Male patients being treated with this medicine are advised to have sperm samples frozen and stored prior to the therapy. Males are advised not to father a child while on treatment and for up to six months after the final dose. •Adcetris treatment may influence the ability to drive or operate machines. If patients feel unwell while on therapy then avoid driving or operating machines. •Adcetris contains 13.2mg sodium (major component of cooking/table salt) in each vial. This is equivalent to 0.7 percent of the prescribed maximum daily dietary intake of sodium for an adult.
Overdose: Seek emergency medical attention or call your healthcare professional team. Missed Dose: Patients are advised to call their healthcare professionals in case they miss an appointment for their brentuximab vedotin injection. Storage: Store unopened vial of Adcetris 50 mg at temperature 2°C to 8°C (36°F to 46°F). It is not recommended to freeze this medication. Keep the Adcetris vial in the original carton in order to protect from light. Note: The information provided in this article named "Information for the Patient About Adcetris 50 mg", is only for informational purposes and is not served as a substitute for the medical treatment, consultation, diagnosis, of a qualified doctor. FAQs What is ADCETRIS used for?
ADCETRIS is an antibody-drug conjugate used in the treatment of relapsed or refractory Hodgkin lymphoma (HL), systemic anaplastic large cell lymphoma (ALCL), and cutaneous T-cell lymphoma (CTCL). Is ADCETRIS chemotherapy? ADCETRIS is not like traditional chemotherapy. It is available as an antibody drug conjugate made up of three parts: an antibody, a drug, and a linker. How serious is Hodgkin's lymphoma? Hodgkin's lymphoma (HL) is treatable, mainly in its early stages. The 1-year survival rate for all patients diagnosed with Hodgkin's lymphoma is about 92%. The 5-year survival rate is about 86 percent. For patients with stage-4 Hodgkin's lymphoma, the survival rate (SR) is lower. How long does treatment for Hodgkin lymphoma take? A typical chemo regimen for HL (Hodgkin lymphoma) might involve around 6-cycles of a combination of medications, given over a period of 6-months. There are several different ways of giving chemotherapy. How much does ADCETRIS cost? As with all medications, the cost of Adcetris can vary. In order to get the best price and buy adcetris online, kindly reach out to us at our TOLL-FREE Number: 1800-889-1064. Source – https://namepatientprogram.blogspot.com/2022/04/information-for-patient-about.html
